Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung Cancer

doi:10.3389/fonc.2020.572853

	Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung Cancer
	Wang, Wenxian 4,5,6; Huang, Zhangzhou 1; Yu, Zongyang 9; Zhuang, Wu 1; Zheng, Weijun 8; Cai, Zhijian 7; Shi, Lei 2; Yu, Xinmin 4,5,6; Lou, Guangyuan 4,5,6; Hong, Wei 4,5,6
刊名	FRONTIERS IN ONCOLOGY
	2020-10-09
卷号	10
关键词	immune checkpoint inhibitor non-small cell lung cancer biomarker chemotherapy lung immune prognostic index
ISSN号	2234-943X
DOI	10.3389/fonc.2020.572853
通讯作者	Chen, Ming(chenming@zjcc.org.cn) ; Song, Zhengbo(songzb1983@163.com)
英文摘要	Background Lung immune prognostic index (LIPI) status was recently developed to predict responses to immune checkpoint inhibitor (ICI) treatments. However, it is unclear whether LIPI is a prognostic index for both patients treated with ICI monotherapy and patients treated with ICIs combined with chemotherapy (ICIs CC). Methods This retrospective study established the patterns of LIPI in Chinese patients with advanced non-small cell lung cancer. Lung immune prognostic index based on the derived neutrophil-to-lymphocyte ratio greater than 3 and lactate dehydrogenase greater than the upper limit of normal was developed to characterize good, intermediate, or poor LIPI status. Associations between LIPI status and progression-free survival (PFS) and overall survival (OS) were analyzed. Kaplan-Meier curves and Cox proportional hazards models were used to determine survival differences. Results Three hundred thirty patients were included in this study. Of these patients, 216 received ICI monotherapy and 114 received ICIs CC. A good LIPI status was associated with better PFS (6.1 months vs. 2.3 months vs. 2.1 months, P = 0.023) and OS (24.2 months vs. 14.5 months vs. 9.3 months, P < 0.001) in ICI monotherapy compared to intermediate or poor LIPI status. No differences in PFS (17.9 vs. 9.9 months vs. 7.6 months, P = 0.355, respectively) and OS (P = 0.346) were observed in patients who received ICIs CC. Moreover, we found that patients who had an improved LIPI status compared with the baseline value had a longer PFS with ICI monotherapy and LIPI intermediate status (8.4 months vs. 2.1 months vs. 1.4 months, P < 0.001). However, in patients treated with ICIs CC, these dynamic changes were not observed (P = 0.444). Conclusions Lung immune prognostic index status and dynamic changes in LIPI could be prognostic markers of treatment response to ICI monotherapy, but not to ICIs CC. In particular, good LIPI status was associated with a better clinical outcome compared with intermediate and poor LIPI status in ICI monotherapy treatment.
资助项目	National Natural Science Foundation of China[81802276]
WOS关键词	TO-LYMPHOCYTE RATIO ; SERUM LACTATE-DEHYDROGENASE ; EARLY MARKER ; OPEN-LABEL ; NSCLC ; OUTCOMES ; PEMBROLIZUMAB ; ASSOCIATION ; THERAPY ; IMMUNOTHERAPY
WOS研究方向	Oncology
语种	英语
出版者	FRONTIERS MEDIA SA
WOS记录号	WOS:000581168900001
资助机构	National Natural Science Foundation of China
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/104600]
专题	中国科学院合肥物质科学研究院
通讯作者	Chen, Ming; Song, Zhengbo
作者单位	1.Fujian Med Univ, Fujian Prov Canc Hosp, Dept Med Oncol, Canc Hosp, Fuzhou, Peoples R China 2.Hangzhou YITU Healthcare Technol Co Ltd, Hangzhou, Peoples R China 3.Zhejiang Canc Hosp, Zhejiang Key Lab Radiat Oncol, Hangzhou, Peoples R China 4.Chinese Acad Sci, Inst Canc & Basic Med, Hangzhou, Peoples R China 5.Zhejiang Canc Hosp, Hangzhou, Peoples R China 6.Univ Chinese Acad Sci, Canc Hosp, Dept Med Oncol, Hangzhou, Peoples R China 7.Zhejiang Univ, Inst Immunol, Sch Med, Hangzhou, Peoples R China 8.Zhejiang Chinese Med Sch, Coll Publ Hlth, Dept Med Stat, Hangzhou, Peoples R China 9.900th Hosp, Dept Med Oncol, Fuzhou, Peoples R China
推荐引用方式 GB/T 7714	Wang, Wenxian,Huang, Zhangzhou,Yu, Zongyang,et al. Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung Cancer[J]. FRONTIERS IN ONCOLOGY,2020,10.
APA	Wang, Wenxian.,Huang, Zhangzhou.,Yu, Zongyang.,Zhuang, Wu.,Zheng, Weijun.,...&Song, Zhengbo.(2020).Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung Cancer.FRONTIERS IN ONCOLOGY,10.
MLA	Wang, Wenxian,et al."Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung Cancer".FRONTIERS IN ONCOLOGY 10(2020).